Advertisement

Topics

Introduction of universal infant hepatitis B immunisation in the UK- paving the way to elimination.

08:00 EDT 8th October 2018 | BioPortfolio

Summary of "Introduction of universal infant hepatitis B immunisation in the UK- paving the way to elimination."

In May 2016, the World Health Assembly ratified the first ever Global Health Sector Strategy (GHSS) on Viral Hepatitis to eliminate viral hepatitis as a public health threat by 2030. In pursuit of this elimination goal and recognising that hepatitis control through immunisation is an essential foundation of a hepatitis B prevention programme, the World Health Organization set out vaccine coverage targets for both universal and selective childhood immunisation programmes, focusing on preventing mother to child transmission. In August 2017 the UK introduced a hexavalent (DTaP/IPV/Hib/HepB) combination vaccine into the routine childhood immunisation programme, replacing the pentavalent vaccine given to all infants at 8, 12 and 16 weeks. With the addition of the 6th component to protect against hepatitis B the UK finally introduced universal hepatitis B immunisation. Prior to that, the UK had a selective immunisation policy targeting high risk groups for hepatitis B - including infants born to hepatitis B infected mothers. We tell the story of hepatitis B vaccination in the UK, and how we have evolved from selective to a universal infant immunisation programme, the factors considered in hepatitis B vaccine policy decision-making, and the progress towards elimination of viral hepatitis as a public health threat.

Affiliation

Journal Details

This article was published in the following journal.

Name: Human vaccines & immunotherapeutics
ISSN: 2164-554X
Pages:

Links

DeepDyve research library

PubMed Articles [5395 Associated PubMed Articles listed on BioPortfolio]

Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university.

Infant hepatitis B vaccination was introduced into the Expanded Programme on Immunisation (EPI) in Malaysia in 1989. This study aimed to investigate seroprevalence of hepatitis B among UKM pre-clinica...

Observational study of vaccine effectiveness 20 years after the introduction of universal hepatitis B vaccination in Tunisia.

The objectives of this study were to estimate the national prevalence of hepatitis B infection in Tunisia using data from a nationwide survey, to compare results with those obtained in 1996 survey and...

HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.

Elimination of hepatitis C virus (HCV) among people who inject drugs (PWID) is a costly investment, so strategies should not only focus on eliminating the disease, but also on preventing disease resur...

Hepatitis C virus infection in children: How do we prevent it and how do we treat it?

Hepatitis C Virus (HCV) infection is an important contributor to the worldwide burden of liver-related morbidity and mortality. Mother-to-child transmission of HCV ranges from 6-11% in different popul...

Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.

 Disease activity, but also demographics, lifestyle, and comorbidities, may influence alanine aminotransferase (ALT) levels in hepatitis C virus (HCV)-infected patients. Direct-acting antiviral agen...

Clinical Trials [4322 Associated Clinical Trials listed on BioPortfolio]

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study

To demonstrate that colocation treatment of substance use disorder and Hepatitis C infection concurrently while proving addiction counselling will achieve increased duration of sobriety an...

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) in...

Comparative Immunogenicity Study of Two Hepatitis A Vaccines

Hepatitis A is the most prevalent hepatitis which account for approximately 45% . The susceptible population is Children and adolescence, also the morbidity in adult presented rising trend...

Observational Study of Immune Response to Hepatitis B Childhood Booster

The UK immunisation guidelines recommend that children immunised with an accelerated course of hepatitis B vaccine (i.e. vaccination at 0, 1, 2 and 12 months) receive an additional booster...

Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.

This study is being conducted to assess impact of maternal immunisation against pertussis in infants ≤12 months of age before and after introduction of pertussis maternal immunisation in...

Medical and Biotech [MESH] Definitions

INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).

A family of hepatotropic DNA viruses which contains double-stranded DNA genomes and causes hepatitis in humans and animals. There are two genera: AVIHEPADNAVIRUS and ORTHOHEPADNAVIRUS. Hepadnaviruses include HEPATITIS B VIRUS, duck hepatitis B virus (HEPATITIS B VIRUS, DUCK), heron hepatitis B virus, ground squirrel hepatitis virus, and woodchuck hepatitis B virus (HEPATITIS B VIRUS, WOODCHUCK).

A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article